Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Achievement of SVR12 with DAA-only Combination Therapy Possible in Hepatitis C: BMS
January 26, 2012
- Toho HD Upwardly Revises FY2012 Earnings Forecast Expecting Boosted Sales, Profits
January 25, 2012
- Nichi-Iko, Sanofi to Jointly Develop Remicade Biosimilar
January 25, 2012
- Pfizer Japan Launches Zithromac for Intravenous Use
January 25, 2012
- CMIC HD to Merge 2 CRO Subsidiaries
January 25, 2012
- Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs
January 24, 2012
- Seikagaku Initiates PII Trial for SI-614 for Dry Eye in US
January 24, 2012
- Sosei Announces Collaboration with CEOLIA Pharma
January 24, 2012
- Wakamoto Pharmaceutical Withholds Joint Venture Plan with Major Taiwanese Generics Company
January 23, 2012
- Astellas to Transfer 3 Drugs to Choseido including Tathion
January 23, 2012
- Indications for Alveolar Pyorrhea Removed from Lysozyme HCl
January 23, 2012
- Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System
January 23, 2012
- NPhA’s Iwasaki Says Strength in Securing Profit Weak
January 23, 2012
- GSK Obtains Approval for Paxil CR Tablets, to Comarket with DSP
January 20, 2012
- No. of Patients Not Recommended to Take Generics Down to 40%: Sawai Survey
January 20, 2012
- Teijin Pharma: Bonalon IV Infusion Approved as Japan’s 1st Once-a-Month IV Drug for Osteoporosis
January 20, 2012
- Takeda to Cut 2,800 Jobs in US, Europe by Integrating Operation Sites
January 19, 2012
- Takeda President Hasegawa Envisions Japanese National as Successor
January 19, 2012
- Takeda’s Next Core Product, Novel ARB Azilva Approved
January 19, 2012
- Senju Obtains Approval for Glaucoma Treatment Aiphagan
January 19, 2012
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…